Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPJ3YX)

Drug Name

Tegavivint Drug Info

Synonyms

Tegatrabetan; 1227637-23-1; BC2059; Tegavivint; Tegavivint [INN]; BC-2059; 18AP231HUP; CHEMBL3601411; N-[3,6-bis[[(3S,5R)-3,5-dimethylpiperidin-1-yl]sulfonyl]-10-nitrosoanthracen-9-yl]hydroxylamine; 9,10-Anthracenedione, 2,7-bis(((3R,5S)-3,5-dimethyl-1-piperidinyl)sulfonyl)-, 9,10-dioxime, rel-; TEGAVIVINT [WHO-DD]; UNII-18AP231HUP; SCHEMBL14947676; BDBM50108103; NSC785527; AKOS032946684; NSC-785527; BS-14778; HY-109103; CS-0039507; D71173; 2,7-bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime; rel-2,7-Bis(((3R,5S)-3,5-dimethylpiperidin-1-yl)sulfonyl)anthracene-9,10-dione dioxime

Indication

Disease Entry	ICD 11	Status	REF
Desmoid tumour	2F7C	Phase 1	[1]

Cross-matching ID

PubChem CID: 46212391
TTD Drug ID: DMPJ3YX

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Beta-catenin (CTNNB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Recombinant human endostatin	DMMPCFX	Solid tumour/cancer	2A00-2F9Z	Approved	[3]
C 82	DMEWXFK	Scleroderma	4A42	Phase 1/2	[4]
CEQ-508	DMCR7EF	Familial adenomatous polyposis	2B90.Y	Phase 1/2	[5]
------------------------------------------------------------------------------------

Drug(s) Targeting F-box-like/WD repeat-containing protein TBL1X (TBL1X)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SY-2101	DMRHJOO	Acute promyelocytic leukaemia	2A60.0	Phase 1	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Beta-catenin (CTNNB1)	TTRPKQG	CTNB1_HUMAN	Inhibitor	[2]
F-box-like/WD repeat-containing protein TBL1X (TBL1X)	TTAL6S1	TBL1X_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03459469) Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor. U.S.National Institutes of Health.
2	Tegavivint and the beta-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma. J Natl Cancer Inst. 2019 Nov 1;111(11):1216-1227.
3	Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/beta-catenin signaling pathway. PLoS One. 2014 Sep 18;9(9):e107463.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Current Progress of siRNA/shRNA Therapeutics in Clinical Trials. Biotechnol J. 2011 September; 6(9): 1130-1146.
6	Transducin beta-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma. Haematologica. 2021 Nov 1;106(11):2927-2939.